https://www.businesswire.com/news/home/20230123005190/en/Viewpoint-Molecular-Targeting-Announces-First-Neuroendocrine-Tumor-Patients-Dosed-with-Therapeutic-Intent
0
0
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent - Business Wire
1/23/23 at 2:10pm
Organization
Business Wire
Authors
Details
32 words
Summarize
Cancer Drugs & Medications Health Pharmaceuticals & Biotech Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Business Wire Viewpoint Molecular Targeting®, Inc. alpha-particle therapies precision oncology company
Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, to
Create an account or login to join the discussion